Working… Menu

PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib (PIPA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02389842
Recruitment Status : Active, not recruiting
First Posted : March 17, 2015
Last Update Posted : November 19, 2019
Institute of Cancer Research, United Kingdom
Roche Pharma AG
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Actual Primary Completion Date : October 31, 2018
Estimated Study Completion Date : January 2020